immunotherapy

Grey Wolf raises £10m for tumour ‘illumination’ tech

Immuno-oncology biotech Grey Wolf Therapeutics has raised £10 million in series A financing to develop therapies that increase

Grey Wolf raises £10m for tumour ‘illumination’ tech

https://pharmaphorum.com/news/grey-wolf-raises-10m-for-tumour-illumination-tech/

BMS looks to RNA splicing to boost immunotherapies

Bristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and

BMS looks to RNA splicing to boost immunotherapies

https://pharmaphorum.com/news/bms-looks-to-rna-splicing-to-boost-immunotherapies/

21st Annual Superbugs & Superdrugs Conference

https://pharmaphorum.com/events/21st-annual-superbugs-superdrugs-conference/

Cancer immunotherapy pioneers awarded Nobel medicine prize

Cancer immunotherapy pioneers James Allison and Tasuku Honjo have been awarded this year’s Nobel Prize in Physiology or

Cancer immunotherapy pioneers awarded Nobel medicine prize

https://pharmaphorum.com/news/cancer-immunotherapy-pioneers-awarded-nobel-medicine-prize/

Merck and Pfizer trial cancer combination with Australia’s Immutep

Australian biotech Immutep has begun a clinical trial partnership with Germany’s Merck KGaA and Pfizer to develop a

Merck and Pfizer trial cancer combination with Australia’s Immutep

https://pharmaphorum.com/news/merck-and-pfizer-trial-cancer-combination-with-australias-immutep/

Immuno-Oncology 2018 News: MHRA Interview and New Speaker ImmuneBiotech AB Announced

Just Over 1 Week Until Immuno-Oncology 2018 Commences

Immuno-Oncology 2018 News: MHRA Interview and New Speaker ImmuneBiotech AB Announced

https://pharmaphorum.com/partner-content/immuno-oncology-2018-news-mhra-interview-and-new-speaker-immunebiotech-ab-announced/

Scancell expands cancer research deal with Karolinska Institute

Research will develop drugs in a wider range of cancers

Scancell expands cancer research deal with Karolinska Institute

https://pharmaphorum.com/news/scancell-expands-cancer-research-deal-karolinska/

Immuno-Oncology challenges include identifying patients before therapy, limited responses and biomarker research

Challenges facing Immuno-Oncology industry

Immuno-Oncology challenges include identifying patients before therapy, limited responses and biomarker research

https://pharmaphorum.com/partner-content/immuno-oncology-challenges-include-identifying-patients-before-therapy-limited-responses-and-biomarker-research/

EU regulators reject new use for Opdivo, as Keytruda edges ahead

Keytruda begins to win battle of the immunotherapies

EU regulators reject new use for Opdivo, as Keytruda edges ahead

https://pharmaphorum.com/news/eu-regulators-reject-new-use-for-opdivo-as-keytruda-edges-ahead/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Search

Advanced Search

Trending

immunotherapy